缺血性脑卒中后焦虑和抑郁症状

IF 1.1 3区 医学 Q2 CLINICAL NEUROLOGY
Marthe Kristine Sve, Johanne Kiplesund, Bent Indredavik, Stian Lydersen, Kristin Haugskott Tiller, Ailan Phan, Torgeir Wethal
{"title":"缺血性脑卒中后焦虑和抑郁症状","authors":"Marthe Kristine Sve,&nbsp;Johanne Kiplesund,&nbsp;Bent Indredavik,&nbsp;Stian Lydersen,&nbsp;Kristin Haugskott Tiller,&nbsp;Ailan Phan,&nbsp;Torgeir Wethal","doi":"10.1155/ane/5591145","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <h3> Objective</h3>\n \n <p>To estimate the prevalence of symptoms of anxiety and depression at 3 months, 1 year, and 3 years after ischemic stroke and assess if these are associated with reduced health-related quality of life (HRQOL) or functional disability.</p>\n </section>\n \n <section>\n \n <h3> Design</h3>\n \n <p>This study is a retrospective, longitudinal study.</p>\n </section>\n \n <section>\n \n <h3> Participants</h3>\n \n <p>The participants are patients with first-ever ischemic stroke.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Mood was assessed using Hospital Anxiety and Depression Scale (HADS), HRQOL was determined using EQ-5D-5L. Modified Rankin Scale (mRS) was used to assess functional disability. Included participants had answered the HADS questionnaire at least once during the follow-up period (3 months, 1 year, and 3 years) of the MIDNOR STROKE study. We used logistic mixed effect regression to estimate the prevalence of symptoms of anxiety and depression, reduced HRQOL and functional disability at the three time points. Next, we also used logistic mixed effect regression with symptoms of anxiety or depression as dependent variable, time point as categorical covariate, reduced HRQOL or functional disability, and its interaction with time as covariates.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>In total, 696 participants were included in our study. The prevalence estimates of participants with symptoms of depression were 16.5%, 18.4%, and 18.7% at 3 months, 1 year, and 3 years poststroke, respectively. The estimated prevalences of participants with symptoms of anxiety were 18.3%, 19.8%, and 20.3% at 3 months, 1 year, and 3 years, respectively. Participants with reduced HRQOL or functional disability had a higher risk of having symptoms of depression at 3 months (OR 4.63 [95% CI 2.25–9.81] and OR 4.39 [95% CI 1.83–10.52], respectively), 1 year (OR 5.58 [95% CI 2.86–10.89] and OR 5.43 [95% CI 2.53–11.68], respectively), and 3 years (OR 8.24 [95% CI 3.90–17.41] and OR 6.93 [95% CI 2.98–16.08], respectively). Participants with reduced HRQOL had a higher risk of having symptoms of anxiety at 1 year (OR 3.61 [95% CI 1.72–7.89]), whereas participants with functional disability had a higher risk of having anxiety symptoms at 3 months (OR 3.83 [95% CI 1.30–11.28]), and at 3 years (OR 3.40 [95% CI 1.24–9.36]). Sensitivity analyses with adjustment for age, sex, education, stroke severity, prestroke comorbidity burden, and prestroke cardiovascular disease had only minor effects on the estimates.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>The prevalence of both anxiety and depression symptoms increased during the follow-up. HRQOL and functional disability are associated with symptoms of anxiety and depression. In stroke patients, efforts should focus on improving both HRQOL and functional disability as well as treating/monitoring symptoms of anxiety and depression, as these outcomes are closely related.</p>\n </section>\n </div>","PeriodicalId":6939,"journal":{"name":"Acta Neurologica Scandinavica","volume":"2026 1","pages":""},"PeriodicalIF":1.1000,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ane/5591145","citationCount":"0","resultStr":"{\"title\":\"Symptoms of Anxiety and Depression After Ischemic Stroke\",\"authors\":\"Marthe Kristine Sve,&nbsp;Johanne Kiplesund,&nbsp;Bent Indredavik,&nbsp;Stian Lydersen,&nbsp;Kristin Haugskott Tiller,&nbsp;Ailan Phan,&nbsp;Torgeir Wethal\",\"doi\":\"10.1155/ane/5591145\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n <section>\\n \\n <h3> Objective</h3>\\n \\n <p>To estimate the prevalence of symptoms of anxiety and depression at 3 months, 1 year, and 3 years after ischemic stroke and assess if these are associated with reduced health-related quality of life (HRQOL) or functional disability.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Design</h3>\\n \\n <p>This study is a retrospective, longitudinal study.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Participants</h3>\\n \\n <p>The participants are patients with first-ever ischemic stroke.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Mood was assessed using Hospital Anxiety and Depression Scale (HADS), HRQOL was determined using EQ-5D-5L. Modified Rankin Scale (mRS) was used to assess functional disability. Included participants had answered the HADS questionnaire at least once during the follow-up period (3 months, 1 year, and 3 years) of the MIDNOR STROKE study. We used logistic mixed effect regression to estimate the prevalence of symptoms of anxiety and depression, reduced HRQOL and functional disability at the three time points. Next, we also used logistic mixed effect regression with symptoms of anxiety or depression as dependent variable, time point as categorical covariate, reduced HRQOL or functional disability, and its interaction with time as covariates.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>In total, 696 participants were included in our study. The prevalence estimates of participants with symptoms of depression were 16.5%, 18.4%, and 18.7% at 3 months, 1 year, and 3 years poststroke, respectively. The estimated prevalences of participants with symptoms of anxiety were 18.3%, 19.8%, and 20.3% at 3 months, 1 year, and 3 years, respectively. Participants with reduced HRQOL or functional disability had a higher risk of having symptoms of depression at 3 months (OR 4.63 [95% CI 2.25–9.81] and OR 4.39 [95% CI 1.83–10.52], respectively), 1 year (OR 5.58 [95% CI 2.86–10.89] and OR 5.43 [95% CI 2.53–11.68], respectively), and 3 years (OR 8.24 [95% CI 3.90–17.41] and OR 6.93 [95% CI 2.98–16.08], respectively). Participants with reduced HRQOL had a higher risk of having symptoms of anxiety at 1 year (OR 3.61 [95% CI 1.72–7.89]), whereas participants with functional disability had a higher risk of having anxiety symptoms at 3 months (OR 3.83 [95% CI 1.30–11.28]), and at 3 years (OR 3.40 [95% CI 1.24–9.36]). Sensitivity analyses with adjustment for age, sex, education, stroke severity, prestroke comorbidity burden, and prestroke cardiovascular disease had only minor effects on the estimates.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>The prevalence of both anxiety and depression symptoms increased during the follow-up. HRQOL and functional disability are associated with symptoms of anxiety and depression. In stroke patients, efforts should focus on improving both HRQOL and functional disability as well as treating/monitoring symptoms of anxiety and depression, as these outcomes are closely related.</p>\\n </section>\\n </div>\",\"PeriodicalId\":6939,\"journal\":{\"name\":\"Acta Neurologica Scandinavica\",\"volume\":\"2026 1\",\"pages\":\"\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2026-09-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ane/5591145\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Neurologica Scandinavica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1155/ane/5591145\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Neurologica Scandinavica","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/ane/5591145","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的评估缺血性卒中后3个月、1年和3年焦虑和抑郁症状的患病率,并评估这些症状是否与健康相关生活质量(HRQOL)降低或功能障碍相关。本研究为回顾性、纵向研究。参与者是首次缺血性中风的患者。方法采用医院焦虑抑郁量表(HADS)评价患者情绪,采用EQ-5D-5L测定患者HRQOL。采用改良Rankin量表(mRS)评价功能障碍。纳入的参与者在MIDNOR卒中研究的随访期间(3个月、1年和3年)至少回答了一次HADS问卷。我们使用logistic混合效应回归来估计三个时间点焦虑和抑郁症状、HRQOL降低和功能障碍的患病率。其次,我们还使用logistic混合效应回归,以焦虑或抑郁症状为因变量,时间点为分类协变量,HRQOL降低或功能残疾及其与时间的相互作用为协变量。结果共纳入696名受试者。卒中后3个月、1年和3年,有抑郁症状的参与者患病率分别为16.5%、18.4%和18.7%。在3个月、1年和3年时,有焦虑症状的参与者的估计患病率分别为18.3%、19.8%和20.3%。HRQOL降低或功能障碍的参与者在3个月(分别为or 4.63 [95% CI 2.25-9.81]和or 4.39 [95% CI 1.83-10.52])、1年(分别为or 5.58 [95% CI 2.86-10.89]和or 5.43 [95% CI 2.53-11.68])和3年(分别为or 8.24 [95% CI 3.90-17.41]和or 6.93 [95% CI 2.98-16.08])时出现抑郁症状的风险更高。HRQOL降低的参与者在1年内出现焦虑症状的风险较高(OR 3.61 [95% CI 1.72-7.89]),而功能障碍的参与者在3个月(OR 3.83 [95% CI 1.30-11.28])和3年(OR 3.40 [95% CI 1.24-9.36])时出现焦虑症状的风险较高。对年龄、性别、教育程度、中风严重程度、中风前合并症负担和中风前心血管疾病进行调整的敏感性分析对估计只有轻微的影响。结论焦虑和抑郁症状的患病率在随访期间均有所增加。HRQOL和功能性残疾与焦虑和抑郁症状相关。在脑卒中患者中,应努力改善HRQOL和功能残疾,以及治疗/监测焦虑和抑郁症状,因为这些结果密切相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Symptoms of Anxiety and Depression After Ischemic Stroke

Objective

To estimate the prevalence of symptoms of anxiety and depression at 3 months, 1 year, and 3 years after ischemic stroke and assess if these are associated with reduced health-related quality of life (HRQOL) or functional disability.

Design

This study is a retrospective, longitudinal study.

Participants

The participants are patients with first-ever ischemic stroke.

Methods

Mood was assessed using Hospital Anxiety and Depression Scale (HADS), HRQOL was determined using EQ-5D-5L. Modified Rankin Scale (mRS) was used to assess functional disability. Included participants had answered the HADS questionnaire at least once during the follow-up period (3 months, 1 year, and 3 years) of the MIDNOR STROKE study. We used logistic mixed effect regression to estimate the prevalence of symptoms of anxiety and depression, reduced HRQOL and functional disability at the three time points. Next, we also used logistic mixed effect regression with symptoms of anxiety or depression as dependent variable, time point as categorical covariate, reduced HRQOL or functional disability, and its interaction with time as covariates.

Results

In total, 696 participants were included in our study. The prevalence estimates of participants with symptoms of depression were 16.5%, 18.4%, and 18.7% at 3 months, 1 year, and 3 years poststroke, respectively. The estimated prevalences of participants with symptoms of anxiety were 18.3%, 19.8%, and 20.3% at 3 months, 1 year, and 3 years, respectively. Participants with reduced HRQOL or functional disability had a higher risk of having symptoms of depression at 3 months (OR 4.63 [95% CI 2.25–9.81] and OR 4.39 [95% CI 1.83–10.52], respectively), 1 year (OR 5.58 [95% CI 2.86–10.89] and OR 5.43 [95% CI 2.53–11.68], respectively), and 3 years (OR 8.24 [95% CI 3.90–17.41] and OR 6.93 [95% CI 2.98–16.08], respectively). Participants with reduced HRQOL had a higher risk of having symptoms of anxiety at 1 year (OR 3.61 [95% CI 1.72–7.89]), whereas participants with functional disability had a higher risk of having anxiety symptoms at 3 months (OR 3.83 [95% CI 1.30–11.28]), and at 3 years (OR 3.40 [95% CI 1.24–9.36]). Sensitivity analyses with adjustment for age, sex, education, stroke severity, prestroke comorbidity burden, and prestroke cardiovascular disease had only minor effects on the estimates.

Conclusion

The prevalence of both anxiety and depression symptoms increased during the follow-up. HRQOL and functional disability are associated with symptoms of anxiety and depression. In stroke patients, efforts should focus on improving both HRQOL and functional disability as well as treating/monitoring symptoms of anxiety and depression, as these outcomes are closely related.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Acta Neurologica Scandinavica
Acta Neurologica Scandinavica 医学-临床神经学
CiteScore
6.70
自引率
2.90%
发文量
161
审稿时长
4-8 weeks
期刊介绍: Acta Neurologica Scandinavica aims to publish manuscripts of a high scientific quality representing original clinical, diagnostic or experimental work in neuroscience. The journal''s scope is to act as an international forum for the dissemination of information advancing the science or practice of this subject area. Papers in English will be welcomed, especially those which bring new knowledge and observations from the application of therapies or techniques in the combating of a broad spectrum of neurological disease and neurodegenerative disorders. Relevant articles on the basic neurosciences will be published where they extend present understanding of such disorders. Priority will be given to review of topical subjects. Papers requiring rapid publication because of their significance and timeliness will be included as ''Clinical commentaries'' not exceeding two printed pages, as will ''Clinical commentaries'' of sufficient general interest. Debate within the speciality is encouraged in the form of ''Letters to the editor''. All submitted manuscripts falling within the overall scope of the journal will be assessed by suitably qualified referees.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书